Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.
big data
drug development
drug repurposing
omics
precision medicine
Journal
Annual review of pharmacology and toxicology
ISSN: 1545-4304
Titre abrégé: Annu Rev Pharmacol Toxicol
Pays: United States
ID NLM: 7607088
Informations de publication
Date de publication:
06 01 2020
06 01 2020
Historique:
pubmed:
25
7
2019
medline:
12
11
2020
entrez:
25
7
2019
Statut:
ppublish
Résumé
The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.
Identifiants
pubmed: 31337270
doi: 10.1146/annurev-pharmtox-010919-023537
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-352Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States